BodyTech - a new wave of medical devices product liability litigation?
Every industry is affected by advances in technology including artificial intelligence, robotics and the Internet of Things. The medical and healthcare sectors are no exception, and digital health innovation is progressing at a rapid pace. The growing market of the Internet of Medical Things (IoMT)) and BodyTech/wearable devices is likely to have a significant impact on the product liability regime.
1 of 5 Insights
HealthTech, BodyTech, MedTech, LifestyleTech – what are they?
With some creativity and a bit of know-how, nearly any industry can set foot into the technology world and add a 'tech' suffix to the sector name: fintech, fashtech, proptech, edtech – and, of course, the health and welfare industry is also realising the benefits of intersecting health, fitness, medicine and the mind with technology, leading to a raft of new tech verticals.
3 of 5 Insights
Hearing, Seeing, Moving - the miracle of neural prosthetics
When talking about developments in medical research and treatment it has become customary to hear expressions such as "break-through", "revolution", "new paradigm" and "game-changer". Indeed, from the post-war generation onwards, the developed world has been treated to a series of advances in medical technology.
4 of 5 Insights
Protecting prosthetics patients and intellectual property
As with all areas of medical technology, where there is innovation, then regulation and intellectual property issues are not far behind. This is illustrated by the regulatory framework surrounding neural prosthetics.
5 of 5 Insights
Life Sciences Organisation sets out the UK stall
Brexit and the life sciences sector: The UK Government's offer to the EU
New government code of conduct for data-driven technologies in the health and care industries
by Colin McCall
Brexit and the life sciences sector: what is the relevance of the transition (implementation) period?
Brexit and the life sciences sector: guidelines for 'no deal'
New trade secrets law takes effect in UK
by Mark Owen and Louise Popple
Dutch Supreme Court ruling on claim interpretation in Resolution v AstraZeneca
High Court considers meaning of "defect" under the Consumer Protection Act 1987